A Phase 3 interventional study of TAK-771 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN), sponsored by Takeda. Completed at 23 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan — 7 open to participants now, 9 under way, 8 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan.
Among the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan, this one is the 15th largest by enrollment, is one of 2 that started in 2022, is one of 12 in phase 3, and was the 8th registered.
137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.
Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →7 of the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan are open now. Recruiting first, the newest first:
argenx · Sites in Japan, United States, Argentina and 22 more countries
Ages 18+
argenx · Sites in Japan, United States, Argentina and 28 more countries
Ages 18+
Takeda · Sites in Japan, United States, Argentina and 8 more countries
Ages 18+
Dianthus Therapeutics · Sites in Japan, United States, Argentina and 28 more countries
Ages 18–75
Sanofi · Sites in Japan, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 13
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 39 across 84 interventional studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
Median enrollment 160 across the 16 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 7 studies filed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating — fewer than ten, so there is no comparison to draw.
5 of the studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327114Phase 3Janssen Research & Development, LLCEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2026-12-15 |
| NCT06290141Phase 3SanofiA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2027-07-09 |
| NCT06920004Phase 3argenxA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | 2027-09 |
| NCT07091630Phase 3argenxA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | 2027-10-07 |
| NCT04280718argenxA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN)
The participants will be treated with TAK-771 for 45 months as a maximum.
There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CIDP participants only - INCAT disability score between 0 and 7 (inclusive). Participants with INCAT scores of 0, 1 (whether from upper or lower extremities), or 2 (if at least 1 point is from an upper extremity) at screening and/or baseline will be required to have a history of significant disability as defined by an INCAT disability score of 2 (must be exclusively from the lower extremities) or greater documented in the medical record. Participants will be eligible if one of the below eligibility criteria are met:
Exclusion Criteria CIDP patients
Participants with any neuropathy of other causes, including:
Participant with other neuropathies (eg, diabetic, lead, porphyric or vasculitic neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, Lyme neuroborreliosis, post radiation neuropathy, hereditary neuropathy with liability to pressure palsies, CMT neuropathies, meningeal carcinomatosis).
CIDP/MMN Patients
Participant with any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of endpoint measures, including (but not limited to) arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy.
(Participants with clinically diagnosed diabetes mellitus who do not have diabetic peripheral neuropathy and who have adequate glycemic control with [HbA1c] level of \<7.5% at screening will be eligible for the study, provided the electrodiagnostic criteria are consistent with the diagnosis of a definite or probable CIDP consistent with the EFNS/PNS 2010 criteria and the participant agrees to maintain adequate glycemic control.)
Participant with a known history of or ARs such as urticaria, breathing difficulty, severe hypotension, or anaphylaxis following administration of human blood products such as human IgG, albumin, or other blood components.
(Clinically non-significant skin reactions, as per the investigator's and the sponsor medical monitor's discretion, do not meet this exclusion criterion. Clinically non-significant skin reactions may include local reactions to injection such as injection site's itching, redness, erythema, or swelling.)
Participant with an abnormal laboratory values at screening meeting any one of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
Drug: TAK-771
TAK-771 includes IGI 10% and rHuPH20. Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
Drug: TAK-771
Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Also known as: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse
Relapse was defined as worsening of functional disability defined as an increase of \>=1 point relative to the pre-subcutaneous (pre-SC) treatment baseline score in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. The INCAT disability scale was the most widely used assessment tool to measure the functional activity level of participants with CIDP. The INCAT disability scale consisted of upper and lower extremity components, with a maximum of 5 points for the upper extremities (arm disability) and a maximum of 5 points for the lower extremities (leg disability), which were summed for an overall INCAT disability score ranging from 0 to 10 points, where 0 was normal and 10 was severely incapacitated. An adjusted INCAT disability score was the same as the INCAT disability score, with the only exception in the exclusion of changes from 0 (normal) to 1 (minor symptoms) (or vice versa) in upper limb function.
Time frame: Epoch 1: Baseline up to 6 months
Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN
The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kilopascal (kPa) ranging from 0 to 160 kPa.
Time frame: Epoch 1: Baseline up to 6 months
Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as adverse events that occurred during or after administration of the first dose of investigational product (IP). TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months).
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Serious Adverse Events (SAEs)
SAEs were defined as any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: resulted in death, was life-threatening, required inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, or any other important medical event.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs
Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious Adverse Reactions (ARs) Plus Suspected ARs
Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With SAEs and/or TEAEs Associated With Infusions
Infusion associated SAEs and/or TEAEs were defined as SAEs and/or TEAEs considered to be "infusion-related reactions" by investigators.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs Associated With Infusions
Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible. SAEs and TEAEs associated with infusions were the events considered to be "infusion-related reactions" by investigators.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With TEAEs Temporally Associated With Infusions
TEAEs were defined as adverse events that occurred during or after administration of the first dose of IP. TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months). TEAEs temporally associated with infusions defined as AEs occurring during or within 72 hours after completion of an infusion.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious ARs Plus Suspected ARs Temporally Associated With Infusions
Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion. AEs temporally associated with infusions are defined as AEs occurring during or within 72 hours after completion of an infusion.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Systemic TEAEs Associated With Infusions
Any TEAEs other than local TEAEs were considered a systemic TEAE. Infusion associated TEAEs were defined as TEAE considered to be "infusion-related reactions" by investigators.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions
Any reaction with the medical dictionary for regulatory activities (MedDRA) high-level group term (HLGT) of "Administration site reactions" were considered a local infusion site reaction (local TEAE). In addition, any TEAE with Injection Site Reaction Flag = "Yes" was considered a local TEAE. Infusion associated reaction were defined as event considered to be "infusion-related reactions" by investigators.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or AEs
Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs were reported.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1 and 2 (6 Months): Number of Participants With Positive Binding Antibodies, and Positive Neutralizing Antibodies to rHuPH20
Plasma samples for the detection of anti-rHuPH20 binding and neutralizing antibodies were collected. Participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the Screening and Confirmatory Binding Assay). Positive antibodies were defined as participants who had anti rHuPH20 antibody titer greater than or equal to (\>=) 1:160 at least one time during treatment.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1: Percentage of Participants With Clinical Worsening of CIDP
Clinical Worsening of CIDP was defined as a \>=8 kPa decrease in hand grip strength in the more affected hand OR \>=4 points decrease in Rasch Built Overall Disability Scale (R-ODS) relative to the pre-SC treatment baseline score at 2 consecutive time points. Hand grip strength was measured using the Martin vigorimeter by quantifying air pressure. The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.
Time frame: Epoch 1: Baseline until end of Epoch 1 or relapse (up to 6 months)
Epoch 1 and 2 (6 Months): Time to Relapse in Participants With CIDP
Time to relapse was defined as time from the date of the first SC administration of TAK-771 in Epoch 1 or 2 to the date of relapse.
Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in R-ODS Total Score in Participants With CIDP
The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.
Time frame: Epoch 1: Baseline up to 6 months
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in an Average of Handgrip Strength of Both Hands in Participants With CIDP and MMN
The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kPa ranging from 0 to 160 kPa. Average of grip strength was defined as an average of the two maximum values: maximum of the 3 measurements in the more affected hand and the maximum of the 3 measurements in the less affected hand.
Time frame: Epoch 1: Baseline up to 6 months
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) Total Medical Research Council (MRC) Sum Score in Participants With MMN
The MRC sum score served as a measure of muscle strength. The following muscles on each side of the body were examined and the strength of each muscle was rated according to the MRC scale: deltoids, biceps, wrist extensors, iliopsoas, quadriceps, and anterior tibialis. The MRC scale ranged from 0 to 5, where: 0 = no visible contraction; 1 = visible contraction without movement of the limb; 2 = movement of the limb but not against gravity; 3 = movement against gravity over (almost) the full range; 4 = movement against gravity and resistance; and 5 = normal. All scores from both left and right side of the body were summed to obtain the total MRC sum score. The total MRC sum score ranged from 0 (paralysis) to 60 (normal strength) with higher score indication normal strength.
Time frame: Epoch 1: Baseline up to 6 months
Epoch 1: Number of MMN Participants With Increased Guy's Neurological Disability Scale (GNDS) Score in Upper Limb and Lower Limb Categories
GNDS was a questionnaire which consisted of 12 separate categories (4 to 8 questions per category). The categories included: cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue, and others. In the current study, only 2 categories; upper limb function and the lower limb function was used for assessment of the disability of participants with MMN. The severity of each subscale (including upper limb and lower limb) was graded from 0 (normal function) to 5 (total loss of function) based according to severity and impact on the individual. The total GNDS score was the sum of the 12 separate scores ranging between 0 and 60 with higher scores indicating loss of function.
Time frame: Epoch 1: Baseline up to 6 months
Participants took part in the study at 23 investigative sites in Japan. A total of 26 participants were enrolled and treated in this study, which consisted of two treatment epochs (Epoch 1 and Epoch 2) with two cohorts: chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Cohort 1 and multifocal motor neuropathy (MMN) in Cohort 2.
| Milestone | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Started | 19 | 7 | 0 | 0 |
| Treated | 19 | 7 | 0 | 0 |
| Completed | 17 | 7 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Milestone | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Started | 0 | 0 | 16 | 7 |
| Treated | 0 | 0 | 16 | 7 |
| Completed | 0 | 0 | 15 | 7 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
Relapse was defined as worsening of functional disability defined as an increase of \>=1 point relative to the pre-subcutaneous (pre-SC) treatment baseline score in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. The INCAT disability scale was the most widely used assessment tool to measure the functional activity level of participants with CIDP. The INCAT disability scale consisted of upper and lower extremity components, with a maximum of 5 points for the upper extremities (arm disability) and a maximum of 5 points for the lower extremities (leg disability), which were summed for an overall INCAT disability score ranging from 0 to 10 points, where 0 was normal and 10 was severely incapacitated. An adjusted INCAT disability score was the same as the INCAT disability score, with the only exception in the exclusion of changes from 0 (normal) to 1 (minor symptoms) (or vice versa) in upper limb function.
| percentage of participants | Epoch 1, Cohort 1 (CIDP): TAK-771 |
|---|---|
| Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse | 0 (0.00 to 17.65) |
The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kilopascal (kPa) ranging from 0 to 160 kPa.
| kPa | Epoch 1, Cohort 2 (MMN): TAK-771 |
|---|---|
| Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN | -1.1 ± 12.73 |
TEAEs were defined as adverse events that occurred during or after administration of the first dose of investigational product (IP). TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months).
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 16 | 7 | 11 | 6 |
SAEs were defined as any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: resulted in death, was life-threatening, required inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, or any other important medical event.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Epoch 1 and 2 (6 Months): Number of Participants With Serious Adverse Events (SAEs) | 0 | 0 | 0 | 0 |
Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Participants With Related SAEs | 0 | 0 | 0 | 0 |
| Participants With Related TEAEs | 11 | 5 | 7 | 4 |
Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Participants with Serious ARs Plus Suspected ARs | 0 | 0 | 0 | 0 |
| Participants with non-serious ARs Plus Suspected ARs | 12 | 6 | 7 | 4 |
Infusion associated SAEs and/or TEAEs were defined as SAEs and/or TEAEs considered to be "infusion-related reactions" by investigators.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Participants with SAEs associated with Infusions | 0 | 0 | 0 | 0 |
| Participants with TEAEs associated with Infusions | 9 | 5 | 6 | 4 |
Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible. SAEs and TEAEs associated with infusions were the events considered to be "infusion-related reactions" by investigators.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Participants With Related SAEs Associated With Infusions | 0 | 0 | 0 | 0 |
| Participants With Related TEAEs Associated With Infusions | 9 | 5 | 6 | 4 |
TEAEs were defined as adverse events that occurred during or after administration of the first dose of IP. TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months). TEAEs temporally associated with infusions defined as AEs occurring during or within 72 hours after completion of an infusion.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Epoch 1 and 2 (6 Months): Number of Participants With TEAEs Temporally Associated With Infusions | 12 | 6 | 7 | 4 |
Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion. AEs temporally associated with infusions are defined as AEs occurring during or within 72 hours after completion of an infusion.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Participants with Serious ARs Plus Suspected ARs Temporally Associated with Infusions | 0 | 0 | 0 | 0 |
| Participants with Non-serious ARs Plus Suspected ARs Temporally Associated with Infusions | 12 | 6 | 7 | 4 |
Any TEAEs other than local TEAEs were considered a systemic TEAE. Infusion associated TEAEs were defined as TEAE considered to be "infusion-related reactions" by investigators.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Epoch 1 and 2 (6 Months): Number of Participants With Systemic TEAEs Associated With Infusions | 3 | 4 | 3 | 2 |
Any reaction with the medical dictionary for regulatory activities (MedDRA) high-level group term (HLGT) of "Administration site reactions" were considered a local infusion site reaction (local TEAE). In addition, any TEAE with Injection Site Reaction Flag = "Yes" was considered a local TEAE. Infusion associated reaction were defined as event considered to be "infusion-related reactions" by investigators.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions | 9 | 5 | 5 | 4 |
Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs were reported.
| infusions | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Epoch 1 and 2 (6 Months): Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or AEs | 2 | 0 | 0 | 1 |
Plasma samples for the detection of anti-rHuPH20 binding and neutralizing antibodies were collected. Participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the Screening and Confirmatory Binding Assay). Positive antibodies were defined as participants who had anti rHuPH20 antibody titer greater than or equal to (\>=) 1:160 at least one time during treatment.
| Participants | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Participants with Positive Antibodies | 2 | 2 | 3 | 2 |
| Participants with Positive Neutralizing Antibodies | 0 | 0 | 0 | 0 |
Clinical Worsening of CIDP was defined as a \>=8 kPa decrease in hand grip strength in the more affected hand OR \>=4 points decrease in Rasch Built Overall Disability Scale (R-ODS) relative to the pre-SC treatment baseline score at 2 consecutive time points. Hand grip strength was measured using the Martin vigorimeter by quantifying air pressure. The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.
| percentage of participants | Epoch 1, Cohort 1 (CIDP): TAK-771 |
|---|---|
| Epoch 1: Percentage of Participants With Clinical Worsening of CIDP | 21.1 (8.51 to 43.33) |
Time to relapse was defined as time from the date of the first SC administration of TAK-771 in Epoch 1 or 2 to the date of relapse.
| weeks | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 |
|---|---|---|
| Epoch 1 and 2 (6 Months): Time to Relapse in Participants With CIDP | NA (NA to NA) | NA (NA to NA) |
The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.
| score on scale | Epoch 1, Cohort 1 (CIDP): TAK-771 |
|---|---|
| Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in R-ODS Total Score in Participants With CIDP | 0.1 ± 3.24 |
The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kPa ranging from 0 to 160 kPa. Average of grip strength was defined as an average of the two maximum values: maximum of the 3 measurements in the more affected hand and the maximum of the 3 measurements in the less affected hand.
| kPa | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 |
|---|---|---|
| Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in an Average of Handgrip Strength of Both Hands in Participants With CIDP and MMN | 4.03 ± 9.749 | -0.36 ± 10.613 |
The MRC sum score served as a measure of muscle strength. The following muscles on each side of the body were examined and the strength of each muscle was rated according to the MRC scale: deltoids, biceps, wrist extensors, iliopsoas, quadriceps, and anterior tibialis. The MRC scale ranged from 0 to 5, where: 0 = no visible contraction; 1 = visible contraction without movement of the limb; 2 = movement of the limb but not against gravity; 3 = movement against gravity over (almost) the full range; 4 = movement against gravity and resistance; and 5 = normal. All scores from both left and right side of the body were summed to obtain the total MRC sum score. The total MRC sum score ranged from 0 (paralysis) to 60 (normal strength) with higher score indication normal strength.
| score on scale | Epoch 1, Cohort 2 (MMN): TAK-771 |
|---|---|
| Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) Total Medical Research Council (MRC) Sum Score in Participants With MMN | -0.3 ± 3.59 |
GNDS was a questionnaire which consisted of 12 separate categories (4 to 8 questions per category). The categories included: cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue, and others. In the current study, only 2 categories; upper limb function and the lower limb function was used for assessment of the disability of participants with MMN. The severity of each subscale (including upper limb and lower limb) was graded from 0 (normal function) to 5 (total loss of function) based according to severity and impact on the individual. The total GNDS score was the sum of the 12 separate scores ranging between 0 and 60 with higher scores indicating loss of function.
| Participants | Epoch 1, Cohort 2 (MMN): TAK-771 |
|---|---|
| Participants with increased GNDS score in Upper Limb | 1 (1.25 to —) |
| Participants with Increased GNDS Score in Lower Limb | 0 (1.57 to —) |
Collected over Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoch 1, Cohort 1 (CIDP): TAK-771 | 0/19 (0%) | 0/19 (0%) | 16/19 (84.2%) |
| Epoch 1, Cohort 2 (MMN): TAK-771 | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Event | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771 | Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771 |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 8/19 | 2/7 | 4/16 | 0/7 |
| Administration site painGeneral disorders | 2/19 | 1/7 | 1/16 | 2/7 |
| Infusion site erythemaGeneral disorders | 0/19 | 1/7 | 0/16 | 2/7 |
| NasopharyngitisInfections and infestations | 2/19 | 2/7 | 3/16 | 0/7 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/19 | 0/7 | 0/16 | 2/7 |
| SinusitisInfections and infestations | 0/19 | 2/7 | 0/16 | 0/7 |
| HeadacheNervous system disorders | 4/19 | 1/7 | 4/16 | 0/7 |
| Injection site pruritusGeneral disorders | 3/19 | 0/7 | 1/16 | 0/7 |
| PruritusSkin and subcutaneous tissue disorders | 3/19 | 0/7 | 2/16 | 1/7 |
| Abdominal distensionGastrointestinal disorders | 0/19 | 1/7 | 0/16 | 1/7 |
Full Analysis Set (FAS) included all enrolled participants who received TAK-771 at least once.
| Age, Continuous(years) | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Total |
|---|---|---|---|
| Mean | 54.9 ± 17.27 | 57.4 ± 15.71 | 55.6 ± 16.59 |
| Sex: Female, Male(Participants) | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Total |
|---|---|---|---|
| Female | 8 | 2 | 10 |
| Male | 11 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 19 | 7 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Epoch 1, Cohort 1 (CIDP): TAK-771 | Epoch 1, Cohort 2 (MMN): TAK-771 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 19 | 7 | 26 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2022 to primary completion in Oct 2025, 45 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →